Mustang Bio (NSDQ:MBIO) said today that it launched a Phase I trial to evaluate the safety and efficacy of intraventricular delivery of CAR T-cells to the brains of people with HER2-positive breast cancer. The 21-patient trial’s primary goal is to determine the recommended dosing regimen for a Phase II trial. Secondary objectives include evaluating the […]